• Vor Bio released a new post hoc analysis from a China Phase 3 trial of telitacicept in generalized myasthenia gravis.
• Results were presented in an oral session at the MGFA Scientific Session during the 2026 AANEM Annual Meeting.
• Patients showed broad, sustained symptom relief through 48 weeks, with more participants reaching very low symptom burden over time.
• Benefits appeared durable once achieved, supporting continued treatment use across a range of starting disease severity.
• Safety remained consistent with earlier reports, with no new issues flagged over the longer follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290805PRIMZONEFULLFEED9835380) on September 29, 2026, and is solely responsible for the information contained therein.